Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: BioPharmaceuticals _ Orphan & Rare Diseases
AesRx

Organization & Developments: AesRx

Parents

2010: » Blockbuster Drug For Sickle Cell Disease? (2010)
2011:AesRx is completing the pre-clinical development program for Aes-103 and expects to begin human clinical trials in 2011.
275 Grove Street, Suite 2-400
Aes-103 works by increasing the affinity of sickle hemoglobin for oxygen.
AesRx is a biopharmaceutical company dedicated to the development of treatments for two orphan diseases.
AesRx's second development program, Aes-210, is targeted to treat certain inflammatory diseases of the lower intestine, includin
Because only red blood cells with no bound oxygen will sickle, increasing the ability of the sickle red blood cells to bind oxyg
Including: chronic hemolytic anemia, chronic pain and acute painful crisis, stroke, acute chest syndrome, and cumulative damage
More than 13 million individuals world-wide are afflicted with sickle cell disease.
Sickle cell disease is a recessive disorder of the hemoglobin which can lead to a wide range of serious, sometimes life-threaten
The Company's lead program (Aes-103) is targeted to the treatment of sickle cell disease.